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more, a short time period (less than 1 year) since transplanta-
tion and increased serum creatinine levels negatively influ-
enced the CAD risk in this patient population.  Conclusion: 
According to current guidelines, the control of modifiable 
cardiovascular risk factors in renal transplant recipients is 
suboptimal. The decreasing CAD risk over time after trans-
plantation may be due to the reduction of immunosuppres-
sive drugs with time and survival bias. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 With improvements in surgical techniques, HLA 
matching and immunosuppression, renal transplanta-
tion has become the treatment of choice for patients with 
end-stage renal disease. Despite the advances in trans-
plantation and the improvements in short-term trans-
plant survival there is increasing concern about the del-
eterious effects of post-transplantation complications on 
long-term survival. Death with a functioning graft is ac-
counting for half of the graft losses in the first 5 years 
after transplantation. Cardiovascular events are the most 
common causes of death after renal transplantation, with 
 Key Words 
 Hypertension   Smoking   Hyperlipidemia   Diabetes   
Risk factor control   Immunosuppression   Kidney 
transplantation   Statins 
 Abstract 
 Background/Aims: The prevalence of cardiovascular dis-
ease in renal transplant recipients is markedly higher than in 
the general population due to the high prevalence of tradi-
tional cardiovascular risk factors, renal transplant function 
impairment and treatment with immunosuppressive drugs 
that affect blood pressure, cholesterol and blood glucose 
levels.  Methods: Cross-sectional analysis using our renal 
transplant clinic cohort investigating (1) the cardiovascular 
risk factors present in this cohort, and (2) estimating their 
impact on the risk of coronary artery disease (CAD) by using 
the Framingham algorithm.  Results: Control of modifiable 
cardiovascular risk factors in 231 renal transplant recipients 
is suboptimal, i.e. 47.2% of patients are hypertensive, 10.3% 
actively smoke, 39.4% have serum cholesterol concentra-
tions  1 200 mg/dl, and 19.7% have diabetes mellitus. Blood 
pressure, age, hyperlipidemia, smoking and diabetes modu-
late the estimated CAD risk in males and females. Further-
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cerebrovascular disease, myocardial infarction, and oth-
er cardiac events accounting for approximately 40% of 
deaths, followed by infections and malignancies  [1] .
 The prevalence of cardiovascular disease (CVD) in re-
nal transplant recipients is significantly higher than in 
the general population. Prevalence of coronary artery 
disease (CAD) and left ventricular hypertrophy is ap-
proximately 15 and 50%, respectively  [2] . The high prev-
alence of CAD is partly explained by traditional cardio-
vascular risk factors such as hypertension, hyperlipid-
emia, smoking and diabetes mellitus  [3–7] . In addition, 
risk factors that are specific to the situation of renal insuf-
ficiency or damage, e.g. proteinuria, chronic inflamma-
tion, increased oxidative stress, thrombogenic factors, 
hyperhomocysteinemia and anemia, may affect the inci-
dence of CVD in both chronic renal failure and end-stage 
kidney disease  [2, 8] . Moreover, it has been documented 
that immunosuppressive drugs may modulate the esti-
mated risk of CAD by affecting blood pressure, choles-
terol and blood glucose in transplant patients  [9] .
 In the present cross-sectional study, we investigated all 
renal transplant patients that were followed consecutive-
ly in our renal transplant clinic in 2004. Data about tra-
ditional cardiovascular risk factors (i.e. age, blood pres-
sure, total cholesterol, smoking status, presence or ab-
sence of diabetes mellitus) as well as nontraditional 
cardiovascular risk factors playing a potential role after 
kidney transplantation (i.e. immunosuppressive therapy, 
duration of dialysis prior to transplantation, renal trans-
plant function, antihypertensive therapy and time elapsed 
since transplantation) were collected. The 10-year risk of 
CAD was estimated with the algorithm proposed by Wil-
son et al. [10] in the Framingham study.
 Patients and Methods 
 Patient Characteristics 
 In 2004, a total of 231 consecutive patients (144 men and 87 
women) were followed at the transplantation center of the Univer-
sity Hospital of Regensburg, Germany. The subjects of this cohort 
had been transplanted between 1986 and 2003 and were included 
into the present cross-sectional study. The study was done in ac-
cordance with the rules of the local ethics committee and the Dec-
laration of Helsinki for clinical studies.
 A medical history was taken and a physical examination was 
performed by a nephrologist. Variables included in the analysis 
were recipient age, gender, ethnicity, body weight, body mass in-
dex (weight in kilograms divided by height in square meters), 
cause of renal failure (type 1 or type 2 diabetes, nephrosclerosis 
including hypertension and renovascular disease, primary glo-
merulonephritis, polycystic kidney disease, systemic lupus ery-
thematosus, other causes), time on dialysis before transplanta-
tion, kidney transplant from a living or deceased donor, presence 
or absence of diabetes mellitus and hypertension, as well as smok-
ing status.
 Blood Pressure 
 Two blood pressure measurements were done with a sphygmo-
manometer from ERKA (Bad Tölz, Germany) after the partici-
pant had been sitting for at least 5 min, and the mean of both 
measurements was used for analysis. Hypertension was catego-
rized according to the JNC-7 definition  [11] : normal (systolic 
 ! 120 mm Hg and diastolic  ! 80 mm Hg), prehypertension (sys-
tolic 120–139 mm Hg or diastolic 80–89 mm Hg), hypertension 
stage 1 (systolic 140–159 mm Hg or diastolic 90–99 mm Hg),
hypertension stage 2 (systolic  6 160 mm Hg or diastolic  6 100 
mm Hg). When systolic and diastolic pressures fell into different 
categories, the higher category was selected for the purpose of 
classification.
 Diabetes Mellitus 
 According to the Framingham study, diabetes mellitus was 
considered present if the participant was under treatment with 
insulin or oral hypoglycemic agents, if casual blood glucose levels 
exceeded 150 mg/dl at two clinic visits or if fasting blood glucose 
levels exceeded 140 mg/dl  [10] .
 Laboratory Values 
 Venous blood was drawn after overnight fast, and serum cre-
atinine, HbA1c, total cholesterol, high-density lipoprotein (HDL), 
low-density lipoprotein (LDL) and triglycerides were measured by 
standard laboratory techniques. These parameters were used 
to subdivide the patient cohort into different categories: total 
cholesterol ( ! 160, 160–199, 200–239, 240–279, and  6 280 mg/
dl), HDL ( ! 35, 35–59, and  6 60 mg/dl), LDL ( ! 130, 130–159, 
and  6 160 mg/dl), and serum creatinine ( ! 1.5, 1.5–3.0, and  1 3.0 
mg/dl).
 Medication 
 Current medication including immunosuppressive drugs, an-
tihypertensive medication (beta-blockers, ACE inhibitors, di-
uretics, angiotensin receptor blockers and calcium antagonists), 
cardiac glycosides, anticoagulants, insulin, oral hypoglycemic 
agents and statins was assessed in all patients.
 Estimation of CAD Risk 
 To estimate the 10-year risk for CAD events in our patient co-
hort, we used the established algorithm proposed by Wilson et al. 
[10] in the Framingham study. This algorithm consists of classical 
cardiovascular risk factors as follows: systolic/diastolic blood 
pressure, total cholesterol, HDL cholesterol, smoking status, pres-
ence or absence of diabetes mellitus, as well as age and gender.
 Statistical Analysis 
 Results are expressed as mean  8 SEM, unless stated other-
wise. Comparisons of continuous variables between groups were 
performed by nonparametric tests, comparisons of categorical 
variables by two-sided   2 or two-sided Fisher’s exact test where 
applicable. SPSS version 12 software package (SPSS Inc., Chicago, 
Ill., USA) was used for statistical analysis.
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 Results 
 The patient characteristics are shown in  table 1 . All 
231 patients enrolled were Caucasians, 144 were males 
and 87 were females. Age did not differ between gender 
(51.3  8 12.5 years in males and 51.3  8 13.8 years in fe-
males). The main cause of renal failure in males was glo-
merulonephritis (n = 48) followed by diabetes (n = 18) and 
polycystic kidney disease (n = 10). In females, the main 
cause of renal failure was glomerulonephritis (n = 16) fol-
lowed by reflux nephropathy (n = 10) and other diseases 
(lupus erythematosus, tuberculosis, sarcoidosis, oxalosis, 
distal tubular acidosis, ANCA-positive small vessel vas-
culitis). The percentage of living donor transplants was 
27% in males versus 19% in females. Time since trans-
plantation was 38.0  8 47.5 months in males and 49.0  8 
39.0 months in females. Dialysis time before transplanta-
tion was on average 4 years in both males (range 0–14 
years) and females (range 0–13 years). Significant differ-
ences between males and females were found concerning 
serum creatinine concentrations (1.9 vs. 1.7 mg/dl, p  ! 
0.05), body mass index (26.3 vs. 25.1, p  ! 0.05), HDL cho-
lesterol (43 vs. 52 mg/dl, p = 0.005), LDL cholesterol (105 
vs. 96 mg/dl, p  ! 0.05) and the number of antihyperten-
sive drugs (2.4 vs. 1.9, p  ! 0.01). The other patient charac-
teristics investigated did not significantly differ between 
genders ( table 1 ).
 CAD Risk and Age 
 The 10-year CAD risk was calculated using the for-
mula established in the Framingham study  [10] . The av-
erage CAD risk was significantly higher in males as com-
pared to females, i.e. 12.6  8 8.7 vs. 8.6  8 8.7% (p  ! 0.01). 
In the present cohort, renal transplant recipients younger 
than 30 years of age had a very low risk of developing 
CAD within the next 10 years (males 2.8  8 0.5%, females 
0.4  8 0.1%). CAD risk rises with increasing age. This is 
even more evident in males as compared to females. Pa-
tients aged  6 71 years exhibit the highest CAD risk, i.e. 
28.7  8 2.7% in males and 14.4  8 3.0% in females (p  ! 
0.01). Whereas males  ! 50 years and  1 61 years show a 
higher risk of CAD compared to females in the respective 
age groups, the CAD risk in the 51–60 years age category 
is equal in males and females ( fig. 1 ;  table 2 ).
 CAD Risk, Blood Pressure and Antihypertensive 
Medication 
 Hypertension plays a pivotal role for CAD risk and 
due to both pre-existing hypertension and immunosup-
pressive therapy renal transplant recipients often have 
elevated blood-pressure. Despite the fact that 90.4% of 
the patients enrolled in this study received antihyper-
tensive treatment, only 122 of the 231 patients (i.e. 52.8%) 
had normal blood pressure. In males [females] the CAD 
risk significantly increases from 9.4  8 1.5% [4.3  8 
1.0%] in patients with normal blood pressure to 18.7  8 
1.2% [12.6  8 2.2%] in patients with hypertension stage 
2 (p  ! 0.01). As compared to males, females show a low-
er risk of CAD throughout all blood pressure categories 
( fig. 1 ;  table 3 ). The mean number of antihypertensive 
drugs is 2.4  8 1.4 in males and 1.9  8 1.2 in females 
ranging in males from 0 (n = 9) to 6 (n = 1) drugs and in 
females from 0 (n = 13) to 5 (n = 3) drugs. In males the 
CAD risk significantly increases from 7.9  8 2.0% in 
males without antihypertensive medication to 15.3  8 
3.3% with 4 antihypertensive drugs (p  ! 0.01). In fe-
males the CAD risk increases from 4.5  8 1.8% without 
antihypertensive treatment to 11.4  8 0.5% with 5 drugs, 
whereas statistical significance was only reached in 
comparison with 3 antihypertensive drugs (11.0  8 2.0, 
p  ! 0.01).
Table 1.  Patient characteristics of renal transplant recipients
Male
(n = 144)
Female
(n = 87)
p
Age, years 51.3812.5 51.3813.8 0.49
Body mass index 26.383.9 25.184.8 0.02
Living donor, % 27.0 19.0 0.13
Dialysis duration, years 4.0 (0–14) 4.0 (0–14) 0.13
Current smoking, % 9.0 12.6 0.2
Hypertension (%) after Tx 47.2 47.1 0.41
Mean systolic blood pressure
mm Hg 138814 139819 0.26
Mean diastolic blood pressure
mm Hg 79811 81812 0.18
Total cholesterol, mg/dl 197848 197840 0.14
HDL cholesterol, mg/dl 43818 52815 0.005
LDL cholesterol, mg/dl 105834 96829 0.04
Triglycerides, mg/dl 2038148 1928113 0.39
Creatinine, mg/dl 1.980.8 1.780.8 0.01
Blood glucose, mg/dl 110836 1098109 0.37
HbA1c, % 5.182.0 5.381.8 0.3
Time since transplantation
months 38847.5 49839.0 0.2
Numbers of antihypertensive
medication 2.481.4 1.981.2 0.002
Statin, % 46.5 54.2 0.41
D ata are shown as mean values 8 SEM.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
, R
eg
en
sb
ur
g
13
2.
19
9.
14
5.
19
5 
- 1
0/
24
/2
01
9 
3:
51
:4
8 
PM
 Banas  /Banas  /Orth  /Langer  /Reinhold  /
Weingart  /Jung  /Krüger  /Krämer  
Nephron Clin Pract 2011;119:c227–c235c230
 CAD Risk, Cholesterol and Treatment with Statins 
 High total cholesterol and particularly high LDL- and 
low HDL-cholesterol are known risk factors for CAD. Of 
the 231 patients investigated, 140 (60.6%) had a total cho-
lesterol  ! 200 mg/dl. Similar to age and blood pressure, 
CAD risk increases with increasing cholesterol levels. 
Male [female] patients with serum cholesterol concentra-
tions  ! 159 mg/dl show a CAD risk of 8.2  8 1.3% [6.8  8 
2.5%]. Total serum cholesterol levels  1 280 mg/dl are as-
sociated with a tendency to a higher CAD risk in females 
Age
<30 31–40 41–50 51–60 61–70
Blood pressure
Normal Hypertension 2Hypertension 1Prehypertension
Total cholesterol
Smoking Yes No Yes NoDiabetes
Smoking Diabetes
** ***
>71
** **
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 Fig. 1. Estimated risk for CAD and its rela-
tionship to traditional cardiovascular risk 
factors.  *  p  ! 0.05,  * *  p  ! 0.01. 
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(28.3  8 4.4%) as compared to males (17.5  8 0.7%), al-
though this gender difference did not reach statistical sig-
nificance ( fig. 1 ;  table 4 ). A significant difference could be 
seen when comparing HDL- and LDL-cholesterol levels, 
however. The CAD risk in male [female] patients with a 
HDL-cholesterol less than 35 mg/dl is significantly high-
er (13.9  8 1.7% [13.0  8 5.6%]) than in patients with HDL 
levels  6 60 mg/dl (5.2  8 0.3% [4.6  8 1.0%] (p  ! 0.001
[p  ! 0.01])). Male [female] patients with a LDL-cholester-
ol  1 160 mg/dl have also a significantly increased CAD 
risk of 17.3  8 2.6% [18.6  8 6.3%] compared to patients 
with LDL levels  ! 130 mg/dl (11.4  8 0.8% [8.3  8 1.1%]) 
(p  ! 0.05 [p  ! 0.001]).
 Treatment with statins lowers significantly the risk of 
CAD in males (with treatment: CAD risk 11.6  8 1.1%; 
without treatment: CAD risk 13.8  8 1.0%, p  ! 0.05) and 
females (with treatment: CAD risk 5.9  8 1.1%; without 
treatment: CAD risk 11.0  8 1.4%, p  ! 0.01) ( fig. 2 ).
 CAD Risk and Diabetes Mellitus 
 Of the 231 patients, 46 (19.7%) had diabetes mellitus. 
The mean HbA1c in patients with diabetes mellitus was 
6.5 ( 8 1.1%) in males and 6.2 ( 8 0.7%) in females. CAD 
risk significantly increases in patients with diabetes mel-
litus in both males and females. Whereas the risk of CAD 
was 11.2 ( 8 0.8%) in males without diabetes, it was sub-
stantially higher in males with diabetes mellitus, i.e. 17.9 
( 8 1.0%; p  ! 0.001). The negative impact of diabetes mel-
litus was also evident in the female population: in females 
with diabetes mellitus the risk of CAD was 17.8 ( 8 1.9%), 
in those without diabetes it was substantially lower, i.e. 
6.3 ( 8 0.7%; p  ! 0.001) ( fig. 1 ).
 Smoking and CAD Risk 
 Smoking is a strong risk factor for the development of 
CVD and also worsens kidney function. Of the 231 pa-
tients, 24 (10.3%) were smokers. Serum creatinine con-
centrations in this study showed no differences between 
smokers and nonsmokers (male smokers 2.0 mg/dl 
( 8 0.9), nonsmokers 1.9 mg/dl ( 8 0.8); female smokers 1.8 
mg/dl ( 8 0.9), female nonsmokers 1.7 mg/dl ( 8 0.7)). 
Smoking is significantly associated with an increased 
CAD risk in males [smokers 12.9 ( 8 0.7%), nonsmokers 
9.7 ( 8 0.8%) (p  ! 0.05)], but not in females [smokers 11.9 
( 8 0.9%), nonsmokers 8.0 ( 8 0.8%) (p = 0.06)] ( fig. 1 ).
 Effects of Time-Depending Variables (Prior and
Post-Transplant) and Renal Function on CAD Risk 
 Since improvement or normalization of renal function 
after transplantation is known to influence CAD risk 
positively and change of renal function is time dependent 
after transplantation, we both analyzed the impact of re-
nal function on the CAD risk score, and the time from 
transplantation, as well as time on dialysis, respectively.
 Creatinine Levels 
 If renal function is categorized into 3 groups ( ! 1.5; 
1.5–3;  1 3.0 mg/dl) in males and females, the average CAD 
risk score is increasing with lower renal function, but this 
Table 2.  CAD risk in % based on the Framingham risk score in 
transplanted males and females according to age
Age Males Females
<30 years 2.880.5 0.480.1
31–40 years 6.481.0 1.680.3
41–50 years 8.480.7 4.681.4
51–60 years 13.281.0 12.781.8
61–70 years 19.881.4 14.281.9
>71 years 28.782.7 14.483.0
D ata are shown as mean values 8 SEM.
Table 3. C AD risk in transplanted males and females according 
to blood pressure
Blood pressure Males Females
Normal 9.481.5 4.381.0
Prehypertension 10.381.3 6.581.0
Hypertension stage 1 14.381.2 11.081.6
Hypertension stage 2 18.781.2 12.682.2
D ata are shown as mean values 8 SEM. The blood pressure 
definitions are based on JNC-7 definitions.
Table 4. C AD risk in transplanted males and females according 
to total cholesterol
Cholesterol Males Females
<159 mg/dl 8.281.3 6.882.5
160–199 mg/dl 10.381.0 8.081.0
200–239 mg/dl 14.481.5 8.081.2
240–279 mg/dl 21.485.3 11.884.5
>280 mg/dl 17.580.7 28.384.4
D ata are given as mean values 8 SEM.
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does not reach statistical significance ( ! 1.5 mg/dl: 12.0  8 
1.3% (males) vs. 7.7  8 1.2% (females); 1.5–3 mg/dl: 12.7 
 8 1.1 vs. 10.4  8 1.7%;  1 3 mg/dl: 15.0  8 1.5 vs. 11.6  8 
1.1%). Further, no correlation with CAD risk could be 
seen if crude serum creatinine levels were analyzed 
(males: r 2 = 0.02, p = 0.12; females: r 2 = 0.004, p = 0.55).
 Time Post-Transplant 
 To assess the relevance between the time since trans-
plantation and the CAD risk score, we performed two 
different approaches. First, we grouped our patient co-
hort according to their time post-transplant:  ! 1 year, 
1–3 years, and  1 3 years post-transplant, and second we 
correlated the time post-transplant with the CAD score. 
We could not detect any association neither after group-
ing the patients, nor if we correlated the time post-trans-
plant with the CAD score (males: r 2 = 0.003, (p = 0.55): 
females: r 2 = 0.0003, p = 0.87). However, the CAD score 
seems to be slightly reduced (n.s.) over time ( ! 1 year: 
14.6  8 2.1 vs. 9.5  8 1.8% (males vs. females); 1–3 years: 
12.4  8 1.1 vs. 9.6  8 1.8%,  1 3 years 12.2  8 0.9 vs. 7.5  8 
1.1%).
 CAD Risk and Time on Dialysis 
 Time on dialysis prior to transplantation is not associ-
ated with a significant increase in CAD risk, neither after 
grouping the patients in 3 different time ranges ( ! 1 year: 
11.3  8 1.9 vs. 8.5  8 2.8% (males vs. females); 1–5 years: 
12.4  8 1.0 vs. 9.3  8 1.3%;  1 5 years: 12.8  8 1.1 vs. 7.7  8 
1.6%), nor after correlation of their crude dialysis time 
with CAD risk (males: r 2 = 0.004, p = 0.47; females: r 2 = 
0.003, p = 0.65).
 Immunosuppressive Therapy and CAD Risk 
 Immunosuppressive therapy consisted of tacrolimus 
(n = 134), cyclosporine (n = 80) or rapamycin (n = 12) in 
combination with mycophenolate mofetil (n = 141) or 
azathioprine (n = 17) and/or steroids. When comparing 
CAD risk in the two different immunosuppressive treat-
ment groups with tacrolimus and cyclosporine no sig-
nificant differences were found in our patient cohort 
[males: tacrolimus 11.9 ( 8 0.8%), cyclosporine 13.3 
( 8 1.5%); females: tacrolimus 9.6 ( 8 1.4%), cyclosporine 
7.8 ( 8 1.4%) ( fig. 2 )].
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 Fig. 2. Estimated risk for CAD and its relationship to additional cardiovascular risk factors.  *  p  ! 0.05,  * *  p  ! 0.01. 
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 Discussion 
 Compared to dialysis patients, a reduction of the rate 
of cardiac death after successful renal transplantation has 
been reported  [12, 13] . However, cardiovascular death is 
still a major problem after transplantation. The aim of the 
present study was to evaluate the occurrence of different 
traditional and nontraditional cardiovascular risk fac-
tors, the extent of treatment/control of modifiable factors 
as well as their contribution to CAD risk. The use of the 
estimated 10-year CAD risk score was intended to iden-
tify patients at low, medium or high CAD risk in our typ-
ical, unselected cohort of renal transplant recipients.
 One main finding of the present study is that the con-
trol of modifiable cardiovascular risk factors in a single 
center cohort of renal transplant recipients in routine 
ambulatory follow-up on average 3–4 years post-trans-
plant is suboptimal according to current guidelines. The 
analysis revealed that 47.2% of patients were hyperten-
sive, 10.3% of patients still smoked, 39.4% of patients 
had total serum cholesterol concentrations above 200 
mg/dl, and 19.7% of patients had diabetes mellitus. In a 
previous study from Halifax investigating patients   7 
years after renal transplantation similar findings have 
been reported: 27% of the patients had systolic blood 
pressure levels  1 140 mm Hg, 23% smoked, 61% had LDL 
cholesterol levels  1 100 mg/dl, and 30.0% had diabetes 
mellitus  [14] .
 These data emphasize the need for increased efforts in 
order to improve control of cardiovascular risk factors in 
renal transplant recipients. Therefore, a further goal of 
our study was to perform an in-depth analysis of the 10 
year-CAD risk by calculating the Framingham algo-
rithm not only for the whole transplant patient popula-
tion investigated, but also for clearly defined subgroups.
 The algorithm developed by Wilson et al.  [10] to pre-
dict CAD in patients without overt CAD was originally 
established in a population with mostly normal renal 
function, and therefore may not be applicable for renal 
transplant recipients. However, the Framingham risk 
score predicted CAD rather well in a large cohort of renal 
transplant recipients, showing only a tendency for under-
estimation of the true incidence of CAD  [15] . Comparing 
a chronic kidney disease (CKD; mean GFR 52.3  8 7.5 ml/
min in males and 53.2  8 7.5 ml/min in females) cohort 
with the Framingham population, Weiner et al.  [16] could 
show that the Framingham risk score underestimated the 
10-year cardiac event rate (13.9 vs. 20.7% in males and 4.8 
vs. 9.7% in females). Notably, in male CKD patients in-
creasing total cholesterol and blood pressure categories 
did not contribute to increased cardiac event rates (in 
contrast to what was observed in the Framingham co-
hort)  [16] . However, the cohort of male CKD patients was 
rather small (n = 357) in this trial and these findings need 
to be confirmed in larger trials.
 The estimated 10-year CAD risk is not only heavily 
influenced by the above mentioned modifiable cardio-
vascular risk factors, but also by factors that cannot be 
modified, i.e. age and sex. Comparing the age-adjusted 
10-year CAD rates with the results from Wilson et al.  [10] 
in the Framingham study population, we could show 
nearly similar findings for hypertension (e.g. hyperten-
sion stage 2 in males: in our cohort CAD risk 18.7 vs. 
20.9% in the Framingham population; in females 12.6 vs. 
14.1%) and HDL-cholesterol ( ! 35 mg/dl 13.9 vs. 15.8% in 
males, 13.0 vs. 14.7% in females;  1 60 mg/dl 5.2 vs. 8.2% 
in males and 4.6 vs. 3.9% in females). Concerning LDL-
cholesterol levels, remarkable differences could be seen 
comparing our results with those of Wilson et al.  [10] . 
The risk was much higher in transplanted females com-
pared to females without a transplant (LDL-cholesterol 
 ! 130 mg/dl 8.3 vs. 2.3%,  1 160 mg/dl 18.6 vs. 10.6%); in 
contrast in males a difference could be noted only in the 
low LDL-cholesterol group ( ! 130 mg/dl 7.3 vs. 11.4%, 
 1 160 mg/dl 17.3 vs. 17.3%). In another study Ducloux et 
al.  [17] prospectively followed 344 renal transplant recip-
ients, registered coronary events and analyzed cardiovas-
cular risk factors. In this population age, male gender, 
smoking status diabetes mellitus, creatinine clearance, 
low HDL-cholesterol and high systolic blood pressure 
were significantly associated with cardiovascular events. 
These data support the clinical value of our calculations 
showing a significant increase in CAD risk with increas-
ing age, hypertension, diabetes mellitus, smoking, low 
HDL-cholesterol and high LDL-cholesterol. According 
to our data, the 10-year CAD risk increases 2- to 3-fold 
with uncontrolled hypertension, 2- to 4-fold with severe 
hypercholesterolemia, 1.5- to 2.5-fold when diabetes mel-
litus is present, and 1.5-fold with active smoking. In ad-
dition, 10-year CAD risk increases up to 10- to 30-fold 
with each 10 years higher age and 1.5-fold with male gen-
der.
 In the population of renal transplant recipients inves-
tigated by Ducloux et al.  [17] , impaired renal transplant 
function was significantly associated with a higher 10-
year CAD risk. In our study, we found no significant cor-
relation between renal function and CAD risk, also if we 
categorize impaired renal transplant function our analy-
sis only showed a trend for impaired renal function to be 
associated with higher 10-year CAD risk; significance 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
, R
eg
en
sb
ur
g
13
2.
19
9.
14
5.
19
5 
- 1
0/
24
/2
01
9 
3:
51
:4
8 
PM
 Banas  /Banas  /Orth  /Langer  /Reinhold  /
Weingart  /Jung  /Krüger  /Krämer  
Nephron Clin Pract 2011;119:c227–c235c234
was presumably missed due to the lower patient number 
in our study and an overall higher CAD risk in our co-
hort. However, this finding is nevertheless important, as 
Meier-Kriesche et al.  [18] have shown that the rate of car-
diovascular death more than doubles when serum cre-
atinine concentrations are elevated to 2.6–4.0 mg/dl (as 
compared to serum creatinine concentrations  ! 1.5 mg/
dl). Interestingly, other time-dependent variables which 
are known to influence CAD risk such as time on dialysis 
or time after transplantation did also not correlate, 
though CAD risk tended to decrease slightly over time 
after transplantation and was lowest (n.s.) in the patient 
group with dialysis duration  ! 1 year. The missing corre-
lation might be due to the rather low number of patients 
studied, as well as the use of the Framingham CAD risk 
score which was developed in the general population and 
might not pick up the additional risk conferred by longer 
dialysis duration or impaired renal function.
 In ‘real life’ the CAD risk could be even higher, since 
in a landmark report Kasiske et al.  [15] have reported that 
the Framingham algorithm underestimates the true risk 
of CAD and that diabetes mellitus and smoking are espe-
cially important risk factors for CAD in renal transplant 
patients.
 Interestingly, we could also see that treatment with 
statins lowers the risk for CAD significantly. Against this 
background, it seems unfortunate that in our cohort only 
46.5% of male and 54.2% of female renal transplant re-
cipients were on statin treatment. Statin treatment in re-
nal transplant recipients is supported by a recent work 
from Soveri et al.  [19] showing that it indeed reduces the 
risk for major cardiovascular events in renal transplant 
recipients.
 The number of post-transplant active smokers in our 
center is lower than in another study, but still reaches 
12.5% (vs. 23% in Halifax  [14] ). Previously reported data 
from our center document that we find significantly 
more active smokers on the waiting list as compared to 
renal transplant recipients  [20] . We had assumed that the 
dramatic change in health and personal situation and the 
fear of a premature graft loss were the reasons to stop 
smoking.
 In summary, control of modifiable cardiovascular risk 
factors in a cohort of renal transplant recipients is subop-
timal according to current guidelines, and blood pres-
sure, age, hyperlipidemia, smoking and diabetes mellitus 
contribute as expected to the estimated CAD risk in kid-
ney transplant recipients. Furthermore, estimated CAD 
risk appears to increase with increasing serum creatinine 
and to decrease with increasing time after transplanta-
tion. One possible explanation for the decreasing CAD 
risk after transplantation may be the reduction of immu-
nosuppressive drugs occurring the longer time since 
transplantation has elapsed. Furthermore, besides sur-
vival bias, cardiovascular risk reduction by means of di-
etary and behavioral changes, as well as drug treatment 
may play a role.
 Disclosure Statement 
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